Jessica Wiley, Author at ELIAS Animal Health

ELIAS Animal Health Expands Scientific Advisory Board

Nov. 23, 2021 — ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment Zachary Wright, DVM, DACVIM (Oncology) and Amanda Foskett, DVM, DACVIM (Oncology) to its scientific advisory board. “I am pleased to add two veterinary oncologists to our advisory board," said Tammie Wahaus, CEO of ELIAS Animal Health. "Drs. Wright and Foskett bring an invaluable perspective on the advancement of animal cancer treatments.” Dr. Wright is the Medical Director at Animal Diagnostics Clinic at VCA Hospitals in Dallas, Texas. He received his veterinary medical degree from Texas A&M University and completed a one year rotating small animal internship in medicine and surgery at VCA West Los Angeles Animal Hospital in Los Angeles, California. Dr. Wright completed his residency in small animal oncology at Texas A&M University and became a Diplomate of the American College of Veterinary Internal Medicine-Oncology in [...]

By Jessica Wiley|2022-01-19T20:01:34-06:00November 23rd, 2021|Categories: News|Tags: elias leadership|0 Comments

ELIAS Animal Health In-Licenses Oncolytic Vaccinia Virus Treatment for Pet Animals from Genelux Corporation

Agreement grants ELIAS Animal Health the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine Nov. 18, 2021 -- Genelux Corporation, a clinical-stage immunotherapy company, recently announced a licensing agreement with ELIAS Animal Health for V-VET1, its clinical-stage animal health product candidate. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis). ELIAS Animal Health is planning clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. “We are thrilled to announce our exclusive license for V-VET1 to help veterinarians treat the many pets who are diagnosed with cancer every year,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Companion animal cancer treatments have made little progress in the past few decades, and this partnership is an exciting step in broadening the cancer treatment options available in veterinary medicine.” [...]

By Jessica Wiley|2022-01-08T14:32:44-06:00November 18th, 2021|Categories: News|Tags: cancer immunotherapy, genelux corporation, oncolytic virus|0 Comments

ELIAS Animal Health Launches Clinical Trial Of Cancer Immunotherapy Treatment For Canine Oral Melanoma

Olathe, Kan., August 31, 2021 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a pilot study of its adoptive T cell therapy combined with surgery and radiotherapy, if indicated, for dogs diagnosed with oral malignant melanoma, a highly metastatic disease and the most common form of oral cancer seen in dogs. Melanoma is widely believed to be chemo-resistant and in this study the adoptive T cell therapy will be administered instead of chemotherapy. This clinical trial will enroll dogs that have been newly diagnosed with oral melanoma but have not yet been treated for their cancer. It is a multi-center, single-arm study with no randomization. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment in the trial. A list of participating sites can be found on the website. Adoptive T cell therapy is [...]

By Jessica Wiley|2022-01-08T14:27:30-06:00August 31st, 2021|Categories: News, Press Releases|Tags: clinical trial, oral melanoma|0 Comments

Long-term bone cancer survivor and ECI® patient featured on local news

Ruby the Greyhound was diagnosed with osteosarcoma in December 2016 and began the ELIAS cancer immunotherapy (ECI®). Today, Ruby is thriving and her story was recently featured on a Kansas City local news channel. Learn more about Ruby, one of five long-term survivors from the ELIAS preliminary study. Read the story

By Jessica Wiley|2020-11-19T20:05:29-06:00November 19th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma|0 Comments

ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs

Ten sites now participating in trial of alternative treatment to chemotherapy for canine osteosarcoma Olathe, Kansas, Nov. 12, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces that 10 investigation sites across the U.S. are now participating in the pivotal trial of ELIAS cancer immunotherapy (ECI®). This marks an expansion of the study ELIAS initiated in May to pursue licensure of ECI treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. The geographical areas served by the clinical trial investigation sites include Southern California, the Intermountain Region, the Desert Southwest, the Chicago metropolitan area, North Texas, the Carolinas, and the Mid-Atlantic region, which includes Southeast Pennsylvania, Virginia and Washington D.C. ELIAS will continue recruiting sites to further expand pet owner access to the trial. To learn more about participating [...]

By Jessica Wiley|2022-01-08T14:27:21-06:00November 12th, 2020|Categories: News, Press Releases|Tags: canine osteosarcoma, clinical trial|0 Comments

Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy

Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience survival times twice that of amputation alone. Median survival time for dogs in the study was 415 days, with one dog developing metastasis then experiencing spontaneous complete remission. Read the full study results. In May, ELIAS Animal Health announced the initiation of a follow-up study to pursue licensure of ECI [...]

By Jessica Wiley|2020-07-27T10:26:01-06:00July 14th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial, results, university of missouri|0 Comments

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin, a type of chemotherapy. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment [...]

By Jessica Wiley|2020-06-16T10:15:26-06:00May 28th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial|0 Comments

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]

By Jessica Wiley|2023-01-06T15:41:25-06:00May 5th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial, translational medicine|0 Comments

ELIAS Animal Health announces appointment of Tammy Ham to Board of Directors

Olathe, Kan., March 18, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment of Tammy Ham to its Board of Directors. Ms. Ham is President of BioNOVUS Innovations LLC, a Kansas City-based firm committed to investing in individuals and organizations who are transforming healthcare, and Chief Executive Officer of CicloMed LLC, a developmental-stage pharmaceutical company focusing on unmet needs in human oncology. “Tammy Ham is an established leader in the healthcare field and a fantastic addition to the ELIAS Board of Directors,” said Tammie Wahaus, CEO of ELIAS. “Her experience in leading the development of pharmaceutical products will prove invaluable as we work toward licensure of our canine cancer immunotherapy.” “I am excited to join the ELIAS Board of Directors and to be part of our region’s vibrant animal health community,” said Ms. Ham. “I am impressed with [...]

By Jessica Wiley|2022-01-20T13:10:05-06:00March 18th, 2020|Categories: News|Tags: elias leadership|0 Comments

ELIAS Animal Health announces new additions to leadership team ahead of clinical study launch

Olathe, Kan., February 26, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced today the appointment of Evan Courtemanche as Vice President of Manufacturing, and Jody Ehrhardt, as Director of Clinical Studies. Evan Courtemanche brings an extensive background in mammalian cell-culture manufacturing and supply chain functions in FDA and USDA-regulated therapeutics, and managing contract manufacturing relationships, both international and domestic. He currently oversees the biologics manufacturing processes and facility where the company’s USDA-regulated cancer immunotherapy is manufactured. Previously, Mr. Courtemanche served in manufacturing leadership and oversight roles for Aratana Therapeutics and Genzyme. Jody Ehrhardt, CCRC, brings more than 25 years of experience in clinical studies in both human and animal sciences. As the Director of Clinical Studies for ELIAS, she manages clinical study development, including protocol composition, study site recruitment and management, and regulatory reporting. Previously, she served as a [...]

By Jessica Wiley|2020-03-18T13:11:54-06:00February 26th, 2020|Categories: News|Tags: canine osteosarcoma, clinical trial|0 Comments

About Jessica Wiley